US Stock Fluctuation: Liquidia Plunges on October 1 Due to Patent Loss, Indication Risks, and Downgraded Rating

Liquidia October 1 Major Decline Interpretation

Keywords: Patent loss, indication risk, rating downgrade

1. On September 30, 2026, the Delaware court determined that YUTREPIA infringed two claims of United Therapeutics' No. 327 patent. Both parties must submit remedial plans within one week. The product may be removed from the PH-ILD indication or face broader sales restrictions. The company stated it will appeal and that it is currently unable to estimate the potential financial impact.

2. On October 1, 2026, BTIG downgraded Liquidia’s rating from “Buy” to “Neutral,” and Raymond James downgraded the rating from “Buy” to “Outperform.” The analysts’ rating adjustments increased downward pressure on the stock price.

(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)